Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. While preparing to go head to head in a rare disease market, the companies have signed up ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

– Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license ...

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS) and ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine targeting a chronic blood disorder. The Carlsbad company develops RNA ...

CARLSBAD, Calif. & OSAKA, Japan, March 11, 2025--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced ...

Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis ...

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal Ionis grants Ono global rights to sapablursen for polycythemia vera in a ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: A live ...

Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted therapeutics with a market capitalization of $5.3 billion, stands at a critical juncture as it navigates a competitive landscape and ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.06 per share a year ago.